RT Journal Article
SR Electronic
T1 UROMODULIN AND RISK OF UPPER URINARY TRACT INFECTIONS: A MENDELIAN RANDOMIZATION STUDY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.18.24309082
DO 10.1101/2024.06.18.24309082
A1 Liyanarachi, Kristin Vardheim
A1 Flatby, Helene
A1 Hallan, Stein
A1 Åsvold, Bjørn Olav
A1 Damås, Jan Kristian
A1 Rogne, Tormod
YR 2024
UL http://medrxiv.org/content/early/2024/06/19/2024.06.18.24309082.abstract
AB Background Observational studies have suggested that uromodulin, produced by the kidneys, may reduce the risk of upper urinary tract infections, but are limited by potential confounding. To address this concern, we conducted a two-sample Mendelian randomization study to explore this association.Methods We identified uncorrelated (r2< 0.01) single nucleotide polymorphisms strongly associated (p<5 × 10−6) with urinary and serum uromodulin from two genome-wide association studies. Both studies accounted for kidney function. Genetic associations for the risk of upper urinary tract infections were extracted from an independent genome-wide association study. Inverse-variance weighted and sensitivity analyses were performed.Results The study included 29,315 and 13,956 participants with measured urinary and serum uromodulin, respectively, and 3,873 and 512,608 subjects with and without upper urinary tract infections. A one standard deviation increase in genetically predicted urinary uromodulin was associated with an odds ratio for upper urinary tract infections of 0.80 (95% confidence interval 0.67 to 0.95, p = 0.01). For serum uromodulin, a one standard deviation increase was associated with an odds ratio of 0.95 (95% confidence interval 0.89 to 1.01, p = 0.12). The results were consistent across sensitivity analyses.Conclusion In this two-sample mendelian randomization study we found that increased levels of genetically predicted urinary uromodulin were associated with a reduced risk of upper urinary tract infections. A similar trend was observed for serum uromodulin. Our findings align with results from traditional observational studies which together support that uromodulin may have a protective role against upper urinary tract infectionsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Samarbeidsorganet Helse Midt-Norge, NTNU (Norwegian University of Science and Technology) (Trondheim, Norway) (KL). Open access funding provided by NTNU Norwegian University of Science and Technology (incl St. Olavs Hospital - Trondheim University Hospital). TR was funded by CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of NIH. None of the authors or their institutions have at any time received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We only used summary-level data from studies with relevant participant consent and ethical approval, and ethical approval from an institutional review board was therefore not necessary for the present study. Links to published GWASs: doi: 10.1681/ASN.2021040491.doi: 10.1172/jci.insight.157035 doi: 10.1093/infdis/jiae231I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors